Skip to content
Home/Companies/Biotech/HTL
HTL

HTL

Biotech·France·Active·9yr hold
Entry
2017
Hold
9yr
Status
Active

Who owns HTL?

HTL is currently owned by Naxicap Partners through NIO I (2017 vintage), since 2017.

Hand-verified · updated 2026-04-21

Naxicap Partners
Investor
Naxicap Partners
NIO I · 2017 · Buyout

Key facts

HQFrance
SectorBiotech
Websitehtlbiotech.com

More from NIO I

Other portfolio companies in the same fund.

Dental Monitoring
Dental Monitoring
Exited 2021
HealthTechFrance· 2019
to
Emera
Active
HealthcareFrance· 2019
Executive IT
Exited 2023
IT ServicesFrance· 2019
to
Finophta
Exited 2019
SoftwareFrance· 2019
to
KEYS ASSET MANAGEMENT
Keys Asset Management
Active
Business ServicesFrance· 2019
MORIA
Moria
Active
MedTechFrance· 2019

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track HTL

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy HTL?

5 strategic and 115financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on HTL.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue